2,250
Views
2
CrossRef citations to date
0
Altmetric
Articles

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens

, , , , , , , , , , & show all

References

  • Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proc. 2016;91(1):101–119. doi: 10.1016/j.mayocp.2015.11.007
  • Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016; 91(7):719–734. doi: 10.1002/ajh.24402
  • Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene. 2008;27(5):663–674. doi: 10.1038/sj.onc.1210691
  • Vacca A, Ria R, Reale A, et al. Angiogenesis in multiple myeloma. Chem Immunol Allergy. 2014;99:180–196. doi: 10.1159/000353312
  • Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005;106(1):125–134. doi: 10.1182/blood-2004-09-3679
  • Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost. 2004;30(3):379–385. doi: 10.1055/s-2004-831051
  • Yamaguchi K, Ogawa K, Katsube T, et al. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res. 2005;25(2A):847–851.
  • Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003;102(13):4504–4511. doi: 10.1182/blood-2003-01-0016
  • Cheng SH, Ng MH, Lau KM, et al. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13. 3, platelet factor 4. Blood. 2007; 109(5):2089–2099. doi: 10.1182/blood-2006-04-018770
  • Yang L, Du J, Hou J, et al. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer. 2011;11:261. doi: 10.1186/1471-2407-11-261
  • Liang P, Cheng SH, Cheng CK, et al. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica. 2013;98(2):288–295. doi: 10.3324/haematol.2012.065607
  • Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi: 10.1016/S1470-2045(14)70442-5
  • Durie B, Harousseau J, Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473. doi: 10.1038/sj.leu.2404284
  • Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128–143. doi: 10.1182/blood-2008-10-184226
  • Cervi D, Yip T-T, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 2008;111(3):1201–1207. doi: 10.1182/blood-2007-04-084798
  • Chang H, Qi C, Yi Q-L, et al. P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105(1):358–360. doi: 10.1182/blood-2004-04-1363
  • Kowalska M, Kaminska J, Fuksiewicz M, et al. A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival. Medical Oncol. 2011;28(1):194–198. doi: 10.1007/s12032-009-9403-9
  • Poruk KE, Firpo MA, Huerter LM, et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prevent. 2010;19(10):2605–2610. doi: 10.1158/1055-9965.EPI-10-0178